Solco Healthcare US, LLC has received FDA approval for the oral lisdexamphetamine dimesylate capsules (ANDA 216266), paving the way for the anticipated entry of a key generic version into the ADHD market. This approval is poised to significantly increase competition for the existing monotherapy, which analysts anticipate will drive substantial and rapid cost savings for both payers and patients as the patent landscape shifts.